NeurologyLive® Friday 5 — June 26, 2026

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

Click the read more or watch now buttons for more details and information about each highlight.

1: Insights on Vibrance-2 Study Results of Alixorexton in Narcolepsy Type 2: Richard K. Bogan, MD, FCCP, FAASM

In a recent interview at SLEEP 2026, Richard K. Bogan, MD, FCCP, FAASM, associate clinical professor at the University of South Carolina School of Medicine, discussed data from a phase 2 study of orexin 2 receptor agonist alixorexton in narcolepsy type 2. [WATCH TIME: 3 minutes]

2: Emerging Biomakers in Perpheral Neuropathy Beyond Neurofilament Light Chain: Brett Morrison, MD, PhD

In a recent interview at the 2026 PNS Annual Meeting, Brett Morrison, MD, PhD, associate professor at Johns Hopkins University, discussed emerging biomarkers outside of neurofilament light chain, including muscle MRI, immune-targeted markers, and microRNA research in peripheral nerve disorders. [WATCH TIME: 3 minutes]

3: Pride Month 2026: Understanding Seizure Risk and Gender-Affirming Hormone Therapy

In honor of Pride Month, held annually in June, neurologists Medha Reddy, MD, and Nicole Rosendale, MD, FAAN, discussed a new analysis suggesting that gender-affirming hormone therapy was not associated with an increased risk of seizure-related hospitalization among transgender women.

4: NeuroVoices: Michael Coleman, PhD, on Understanding Programmed Axon Death and Its Therapeutic Potential

In our latest NeuroVoices Q&A, Michael Coleman, PhD, professor of neuroscience at the University of Cambridge, discussed the biology of programmed axon death, the emergence of SARM1-targeted therapies, and the challenges of translating this pathway into treatments for neurologic conditions.

5: Using Serum Biomarkers to Monitor Multiple Sclerosis Disease Activity: Darin T. Okuda, MD, FAAN, FANA

In a recent interview, Darin T. Okuda, MD, FAAN, FANA, professor of neurology at UT Southwestern Medical Center, discussed the Octave Multiple Sclerosis Disease Activity Test as a complementary tool to MRI and clinical assessment in MS. [WATCH TIME: 6 minutes]

Don’t have time to read or watch a full video interview? Click here to check out our shorts!